Investors had ‘incredibly high’ expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment Moderna’s stock is down as investors digest the highly anticipated Phase 3 results for its experimental cancer vaccine. Moderna’s experimental cancer vaccine is getting a reality check, and that’s not necessarily a bad thing. tumbled about 7.4% at the market open on Monday as investors digested a weekend of chatter about the Phase 3 data for intismeran, the therapeutic cancer vaccine Moderna is developing with Merck. Merck shares Copyright ©2026 MarketWatch, Inc.
All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 The Kospi index in Korea is the leading indicator for the global AI trade — and Goldman just slashed its forecast by 25% Musk says SpaceX’s AI rivals are in trouble, sending their stocks lower How to navigate a market that hinges on just a handful of companies Nvidia, AMD and Broadcom could buy Meta shares as part of $35 billion stock offering Jaimy Lee is a healthcare editor and reporter for MarketWatch. She is based in New York. Intraday Data provided by FACTSET and subject to terms of use.
Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.
Extract — continue reading at the source.
